Research published online in Annals of the Rheumatic Diseases suggests that “high-dose fish oil added to a ‘treat to target’ regimen of conventional disease-modifying treatment in early rheumatoid arthritis (RA) was associated with improved outcomes.” Investigators found that, “among patients receiving fish oil in conjunction with triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine, the likelihood of treatment failure at 1 year was lower than for those given triple therapy alone (hazard ratio 0.28, 95% CI 0.12-0.63, P=0.002).” The researchers also found that “the rate of remission was significantly greater in the fish oil group than among controls (HR 2.17, 95% CI 1.07-4.42, P=0.03).”